Table 2.

The univariate and multivariate analyses of overall survival according to GREB1L expression, after adjusting for other potential predictors in TCGA and GSE13213.

Clinicopathologic variable	Total (N)	HR (95% CI)	p-value
TCGA-LUAD
a.
Gender (male vs. female)	497	0.954 (0.711–1.279)	0.752
Age (> 65 vs. ≤ 65)	487	1.221 (0.907–1.643)	0.188
Number pack years smoked (> 40 vs. ≤ 40)	341	1.026 (0.714–1.475)	0.888
T stage (T2/T3/T4 vs. T1)	494	1.678 (1.187–2.373)	0.003
N stage (N2/N3 vs. N0/N1)	486	2.274 (1.589–3.255)	< 0.001
M stage (M1 vs. M0)	355	2.129 (1.243–3.648)	0.006
Pathologic stage (stage III/IV vs. stage I/II)	490	2.629 (1.924–3.591)	< 0.001
GREB1L (high vs. low)	497	1.554 (1.156–2.088)	0.003
b.
T stage (T2/T3/T4 vs. T1)		1.533 (1.008–2.334)	0.046
Pathologic stage (stage III/IV vs. stage I/II)		2.222 (1.576–3.132)	< 0.001
GREB1L (high vs. low)		1.453 (1.076–1.962)	0.015
GSE13213
a.
Gender (male vs. female)	117	0.736 (0.419–1.293)	0.286
Age (> 65 vs. ≤ 65)	117	1.394 (0.784–2.480)	0.258
Smoking (yes vs. no)	117	1.361 (0.774–2.391)	0.284
T stage (T2/T3/T4 vs. T1)	117	1.539 (0.866–2.735)	0.142
N stage (N2 vs. N0/N1)	117	2.810 (1.543–5.116)	0.001
Pathologic stage (stage III vs. stage I/II)	117	2.974 (1.659–5.331)	< 0.001
EGFR status (mut vs. wt)	117	1.021 (0.574–1.815)	0.945
K-ras status (mut vs. wt)	117	1.530 (0.717–3.267)	0.272
p53 status (mut vs. wt)	117	1.357 (0.764–2.412)	0.298
GREB1L (high vs. low)	117	2.564 (1.408–4.666)	0.002
b.
N stage (N2 vs. N0/N1)		1.147 (0.261–5.037)	0.856
Pathologic stage (stage III vs. stage I/II)		2.217 (0.517–9.515)	0.284
GREB1L (high vs. low)		2.207 (1.195–4.077)	0.011